The technology.

The project can last for four years. In the project, fresh specially adapted technology which will help elderly people experiencing slight dementia will be created. This might involve, for instance reminders so they don’t forget to consider their medication or a scheduled appointment. Furthermore to raising the standard of lifestyle for these seniors the new technologies can make it less difficult for relatives and health care professionals. Related StoriesResearchers discover that stem cell treatment may decrease cognitive impairment linked to dementia with Lewy bodiesBU researcher gets prestigious fellowship to release new project for those who have dementiaStudy discovers high prevalence of dehydration in the elderly living in UK treatment homesToday, up to 9 % of the populace over 60 years have problems with mild dementia, so are there a lot of people who could have use of the brand new technology.James Tursi, Chief Medical Officer of Auxilium. We have been delighted that the trial is usually underway and anticipate that the outcomes may demonstrate the potential of XIAFLEX as a forward thinking acute choice for orthopedic surgeons to take care of Frozen Shoulder syndrome over around six weeks with a minimally invasive treatment choice. Initiation of the Frozen Shoulder syndrome trial represents another essential advancement milestone for Auxilium and we have been excited to progress the 3rd potential indication for XIAFLEX, said Armando Anido, LEADER President and Officer of Auxilium Pharmaceuticals. We think that XIAFLEX symbolizes a pipeline in something and be prepared to develop multiple long term indications, furthermore to its proven advantage in dealing with adult Dupuytren’s contracture in individuals with a palpable cord.